{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T16:07:41Z","timestamp":1785514061593,"version":"3.56.0"},"update-to":[{"DOI":"10.1002\/14651858.cd006332.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T00:00:00Z","timestamp":1663200000000}}],"reference-count":89,"publisher":"Wiley","issue":"9","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd006332.pub4","type":"journal-article","created":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T10:23:24Z","timestamp":1663237404000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Mu-opioid antagonists for opioid-induced bowel dysfunction in people with cancer and people receiving palliative care"],"prefix":"10.1002","volume":"2022","author":[{"given":"Bridget","family":"Candy","sequence":"additional","affiliation":[{"name":"Marie Curie Palliative Care Research Department, Division of Psychiatry; University College London; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Jones","sequence":"additional","affiliation":[{"name":"Marie Curie Palliative Care Research Department, Division of Psychiatry; University College London; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Vickerstaff","sequence":"additional","affiliation":[{"name":"Marie Curie Palliative Care Research Department, Division of Psychiatry; University College London; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip J","family":"Larkin","sequence":"additional","affiliation":[{"name":"UCD School of Nursing, Midwifery and Health Systems and Our Lady's Hospice and Care Services; UCD College of Health Sciences; Dublin Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Stone","sequence":"additional","affiliation":[{"name":"Marie Curie Palliative Care Research Department, Division of Psychiatry; University College London; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,9,15]]},"reference":[{"key":"10.1002\/14651858.CD006332.pub4-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1177\/0269216311418869","article-title":"A randomized, double-blind, active- controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone\/naloxone prolonged-release tablets in patients with moderate\/severe, chronic cancer pain","volume":"26","author":"Ahmedzai","year":"2012","journal-title":"Palliative Medicine"},{"key":"10.1002\/14651858.CD006332.pub4-BIB0002|cit2","unstructured":"Center for Drug Evaluation and Research Medical Review Application number: 205777Orig1s000 www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/205777Orig1s000MedR.pdf"},{"key":"10.1002\/14651858.CD006332.pub4-BIB0003|cit3","unstructured":"Center for Drug Evaluation and Research Risk Assessment and Risk Mitigation Review. Product oxycodone\/naloxone extended-release tablets www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/205777Orig1s000RiskR.pdf"},{"key":"10.1002\/14651858.CD006332.pub4-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1089\/jpm.2014.0362","article-title":"Fixed-dose subcutaneous methylnaltrexone in patients with advanced illness and opioid-induced constipation: results of a randomized, placebo-controlled study and open-label extension","volume":"18","author":"Bull","year":"2015","journal-title":"Journal of Palliative Medicine."},{"key":"10.1002\/14651858.CD006332.pub4-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1002\/ejp.1054","article-title":"A phase III randomized controlled study on the efficacy and improved bowel function of prolonged-release (PR) oxycodone\/naloxone (up to 160\/80 mg daily) vs oxycodone PR","volume":"21","author":"Dupoiron","year":"2017","journal-title":"European Journal of Pain."},{"key":"10.1002\/14651858.CD006332.pub4-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1200\/JCO.2016.70.8453","article-title":"Phase IIb randomized, double-blind, placebo-controlled study of naldemedine for the treatment of opioid-induced constipation in patients with cancer","volume":"35","author":"Katakami","year":"2017","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD006332.pub4-BIB0007|cit7","unstructured":"Report on the deliberation results: naldemedine tosilate Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau. https:\/\/www.pmda.go.jp\/files\/000222647.pdf (assessed 28\/02\/21) 2017"},{"key":"10.1002\/14651858.CD006332.pub4-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"3859","DOI":"10.1200\/JCO.2017.73.0853","article-title":"Randomised phase III and extension studies of naldemedine in patients with opioid-induced constipation and cancer","volume":"35","author":"Katakami","year":"2017","journal-title":"Journal of Clinical Oncology\u00a0"},{"key":"10.1002\/14651858.CD006332.pub4-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1093\/annonc\/mdy118","article-title":"Randomized phase III and extension studies: efficacy and impacts on quality of life of naldemedine in subjects with opioid-induced constipation and cancer","volume":"29","author":"Katakami","year":"2018","journal-title":"Annals of Oncology\u00a0"},{"key":"10.1002\/14651858.CD006332.pub4-BIB0010|cit10","unstructured":"Report on the deliberation results: naldemedine tosilate Pharmaceutical Evaluation Division, Pharmaceutical Safety and Environmental Health Bureau. https:\/\/www.pmda.go.jp\/files\/000222647.pdf (assessed 28\/02\/21) 2017 2017"},{"key":"10.1002\/14651858.CD006332.pub4-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s40880-017-0241-4","article-title":"Efficacy and safety of controlled-release oxycodone\/naloxone versus controlled-release oxycodone in Korean patients with cancer-related pain: a randomized controlled trial","volume":"36","author":"Kim T","year":"2017","journal-title":"Chinese Journal of Cancer"},{"key":"10.1002\/14651858.CD006332.pub4-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.jpainsymman.2007.12.005","article-title":"Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced illness: a double-blind, randomised, parallel group, dose-ranging study","volume":"35","author":"Portenoy","year":"2008","journal-title":"Journal of Pain and Symptom Management"},{"key":"10.1002\/14651858.CD006332.pub4-BIB0013|cit13","unstructured":"Assessment report for Relistor. Procedure No. EMEA\/H\/C\/870 European Medicines Agency. www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/000870\/WC500050566.pdf"},{"key":"10.1002\/14651858.CD006332.pub4-BIB0014|cit14","unstructured":"Center for Drug Evaluation and Research Statistical review. Application 21-964 Food and Drug Administration. www.accessdata.fda.gov (assessed 01\/04\/16) 2008"},{"key":"10.1002\/14651858.CD006332.pub4-BIB0015|cit15","first-page":"39","article-title":"Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients","volume":"7","author":"Slatkin","year":"2009","journal-title":"Journal of Supportive Oncology"},{"key":"10.1002\/14651858.CD006332.pub4-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1177\/026921639601000208","article-title":"An investigation of the ability of oral naloxone to correct opioid-related constipation in patients with advanced cancer","volume":"10","author":"Sykes","year":"1996","journal-title":"Palliative Medicine"},{"key":"10.1002\/14651858.CD006332.pub4-BIB0017|cit17","unstructured":"Assessment report for Relistor. Procedure No. EMEA\/H\/C\/870 European Medicines Agency www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/000870\/WC500050566.pdf (accessed 1 April 2016)"},{"key":"10.1002\/14651858.CD006332.pub4-BIB0018|cit18","unstructured":"Center for Drug Evaluation and Research. Statistical review. Application 21-964 Food and Drug Administration. www.accessdata.fda.gov (assessed 01\/04\/16) 2008. [CRSREF: 2866565]"},{"key":"10.1002\/14651858.CD006332.pub4-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.jpainsymman.2009.02.234","article-title":"Methylnaltrexone treatment of opioid-induced constipation in patients with advanced illness","volume":"38","author":"Chamberlain","year":"2009","journal-title":"Journal of Pain and Symptom Management"},{"key":"10.1002\/14651858.CD006332.pub4-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1056\/NEJMoa0707377","article-title":"Methylnaltrexone for opioid-induced constipation in advanced illness","volume":"358","author":"Thomas","year":"2008","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD006332.pub4-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1002\/ejp.1050","article-title":"Long-term efficacy and safety of oxycodone-naloxone prolonged-release formulation (up to 180\/90 mg daily) - results of the open-label extension phase of a phase III multicenter, multiple-dose, randomized, controlled study","volume":"21","author":"Dupoiron","year":"2017","journal-title":"European Journal of Pain"},{"key":"10.1002\/14651858.CD006332.pub4-BIB0022|cit22","unstructured":"A Multicenter, double-blind, randomized, placebo-controlled trial of the preventive effect of naldemedine on opioid-induced constipation rctportal.niph.go.jp 2021"},{"key":"10.1002\/14651858.CD006332.pub4-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ejpain.2008.06.012","article-title":"A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation","volume":"13","author":"Meissner","year":"2009","journal-title":"European Journal of Pain"},{"key":"10.1002\/14651858.CD006332.pub4-BIB0024|cit24","doi-asserted-by":"crossref","unstructured":"Mori M Ji Y Kumar S Ashikaga T Ades S Phase II trial of subcutaneous methylnaltrexone in the treatment of severe opioid-induced constipation (OIC) in cancer patients: an exploratory study International Journal of Clinical Oncology 2017 22 2 397 404","DOI":"10.1007\/s10147-016-1041-6"},{"key":"10.1002\/14651858.CD006332.pub4-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1111\/j.1742-1241.2008.01820.x","article-title":"Patient assessment of a novel therapeutic approach for the treatment of severe, chronic pain","volume":"62","author":"Nadstawek","year":"2008","journal-title":"International Journal of Clinical Practice"},{"issue":"1","key":"10.1002\/14651858.CD006332.pub4-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1186\/s13063-020-04385-0","article-title":"Comparing the effectiveness of magnesium oxide and naldemedine in preventing opioid-induced constipation: a proof of concept, single institutional, two arm, open-label, phase II, randomized controlled trial: the MAGNET study","volume":"21","author":"Ozaki","year":"2020","journal-title":"Trials"},{"key":"10.1002\/14651858.CD006332.pub4-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.clinthera.2015.02.010","article-title":"Treatment with prolonged-release oxycodone\/naloxone improves pain relief and opioid-induced constipation compared with prolonged-release oxycodone in patients with chronic severe pain and laxative-refractory constipation","volume":"37","author":"Poelaert","year":"2015","journal-title":"Clinical Therapeutics"},{"key":"10.1002\/14651858.CD006332.pub4-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/j.jpain.2008.06.014","article-title":"Analgesic efficacy and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain","volume":"9","author":"Vondrackova","year":"2008","journal-title":"Journal of Pain"},{"key":"10.1002\/14651858.CD006332.pub4-BIB0029|cit29","first-page":"S204","article-title":"Methylnaltrexone bromide in the treatment of opioid-induced constipation in lung cancer patients. Is it effective?","volume":"9","author":"Dimitroulis","year":"2014","journal-title":"Journal of Thoracic Oncology"},{"key":"10.1002\/14651858.CD006332.pub4-BIB0030|cit30","unstructured":"Clinical study to investigate the efficacy, safety and tolerability of naloxone in patients with opioid induced constipation EUCTR 2017"},{"key":"10.1002\/14651858.CD006332.pub4-BIB0031|cit31","unstructured":"A study to demonstrate improvement in symptoms of constipation in subjects that require around-the-clock opioid pain killer therapy clinicaltrials.gov\/ct2\/show\/NCT01438567"},{"key":"10.1002\/14651858.CD006332.pub4-BIB0032|cit32","unstructured":"To demonstrate equivalence in analgesic efficacy & bowel function between OXN PR higher dose & lower dose tablet strengths in subjects with non-cancer or cancer pain clinicaltrials.gov\/ct2\/show\/NCT02321397"},{"key":"10.1002\/14651858.CD006332.pub4-BIB0033|cit33","unstructured":"Study of methylnaltrexone in opioid-induced constipation patients clinicaltrials.gov\/ct2\/show\/NCT02574819"},{"key":"10.1002\/14651858.CD006332.pub4-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.pain.2013.04.024","article-title":"A phase 2, double-blind, randomized, placebo-controlled, dose-escalation study to evaluate the efficacy, safety, and tolerability of naloxegol in patients with opioid-induced constipation","volume":"154","author":"Webster","year":"2013","journal-title":"Pain"},{"key":"10.1002\/14651858.CD006332.pub4-BIB0035|cit35","unstructured":"Gupta P Naloxegol in treating patients with stage IIIB-IV non-small cell lung cancer ClinicalTrials.gov 2017"},{"key":"10.1002\/14651858.CD006332.pub4-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1472-684X-13-42","article-title":"Clinical evaluation of the efficacy of methylnaltrexone in resolving constipation induced by different opioid subtypes combined with laboratory analysis of immunomodulatory and antiangiogenic effects of methylnaltrexone","volume":"13","author":"Neefjes","year":"2014","journal-title":"BMC Palliative Care"},{"key":"10.1002\/14651858.CD006332.pub4-BIB0037|cit37","doi-asserted-by":"crossref","unstructured":"Peppin J RCT: methylnaltrexone in patients with advanced illness with opioid induced constipation Journal of Pain 2013 14 S62","DOI":"10.1016\/j.jpain.2013.01.586"},{"key":"10.1002\/14651858.CD006332.pub4-BIB0038|cit38","unstructured":"Wong A A multi-centre, randomised, phase IV study to compare the efficacy of oxycodone\/naloxone verses oxycodone prolonged release tablets in patients with advanced cancer ACTRN12619001282178 ANZCTR 2019"},{"key":"10.1002\/14651858.CD006332.pub4-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1007\/s00482-012-1246-1","article-title":"Is the pharmacological treatment of constipation in palliative care evidence based? A systematic literature review","volume":"26","author":"Bader","year":"2012","journal-title":"Der Schmerz."},{"key":"10.1002\/14651858.CD006332.pub4-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1586\/egh.12.63","article-title":"Methylnaltrexone for the treatment of opioid-induced constipation","volume":"7","author":"Bader","year":"2013","journal-title":"Expert Review of Gastroenterology and Hepatology"},{"key":"10.1002\/14651858.CD006332.pub4-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0028-3908(85)90072-3","article-title":"The use of quaternary narcotic antagonists in opiate research","volume":"24","author":"Brown","year":"1985","journal-title":"Neuropharmacology"},{"key":"10.1002\/14651858.CD006332.pub4-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/ajg.2011.30","article-title":"Opioid-induced constipation: challenges and therapeutic opportunities","volume":"106","year":"2011","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD006332.pub4-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1111\/nmo.12417","article-title":"Emerging treatments in neurogastroenterology: a multidisciplinary working group consensus statement on opioid-induced constipation","volume":"26","author":"Camilleri","year":"2014","journal-title":"Neurogastroenterology and Motility"},{"issue":"5","key":"10.1002\/14651858.CD006332.pub4-BIB0044|cit44","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003448.pub4","article-title":"Laxatives for the management of constipation in people receiving palliative care","author":"Candy","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD006332.pub4-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"e58","DOI":"10.1016\/S1470-2045(12)70040-2","article-title":"Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC","volume":"13","author":"Caraceni","year":"2012","journal-title":"Lancet Oncology"},{"key":"10.1002\/14651858.CD006332.pub4-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1016\/j.jpainsymman.2013.11.004","article-title":"Methylnaltrexone in palliative care: further research is needed","volume":"47","author":"Clark","year":"2014","journal-title":"Journal of Pain and Symptom Management"},{"key":"10.1002\/14651858.CD006332.pub4-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1111\/j.1365-2036.2008.03689.x","article-title":"Gastrointestinal side effects in chronic opioid users: results from a population-based survey","volume":"27","author":"Cook","year":"2008","journal-title":"Alimentary Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD006332.pub4-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"269","DOI":"10.2147\/CEOR.S61602","article-title":"Opioid-induced constipation in patients with chronic noncancer pain in the USA, Canada, Germany, and the UK: descriptive analysis of baseline patient-reported outcomes and retrospective chart review","volume":"6","author":"Coyne","year":"2014","journal-title":"Clinicoeconomic Outcomes Research"},{"key":"10.1002\/14651858.CD006332.pub4-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1517\/13543784.2011.592830","article-title":"Novel opioid antagonists for opioid-induced bowel dysfunction","volume":"20","author":"Diego","year":"2011","journal-title":"Expert Opinion on Investigational Drugs"},{"key":"10.1002\/14651858.CD006332.pub4-BIB0050|cit50","unstructured":"Clinical pharmacology and biophaceutics review: application number: 208854Orig1s000 accessdata.fda.gov 2017"},{"key":"10.1002\/14651858.CD006332.pub4-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1038\/ajg.2013.169","article-title":"Efficacy of pharmacological therapies for the treatment of opioid-induced constipation: systematic review and meta-analysis","volume":"108","author":"Ford","year":"2013","journal-title":"American Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD006332.pub4-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1177\/1049909106289068","article-title":"The adverse effects of morphine: a prospective survey of common symptoms during repeated dosing for chronic cancer pain","volume":"23","author":"Glare","year":"2006","journal-title":"American Journal of Hospice Palliative Care"},{"key":"10.1002\/14651858.CD006332.pub4-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"325","DOI":"10.5055\/jom.2015.0282","article-title":"Impact of constipation on opioid therapy management among long-term opioid users, based on a patient survey","volume":"11","author":"Gupta","year":"2015","journal-title":"Journal of Opioid Management"},{"key":"10.1002\/14651858.CD006332.pub4-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.jclinepi.2011.01.012","article-title":"GRADE guidelines 6. Rating the evidence--imprecision","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD006332.pub4-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jclinepi.2012.01.006","article-title":"GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes","volume":"66","author":"Guyatt","year":"2013","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD006332.pub4-BIB0056|cit56","volume-title":"In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011)","author":"Higgins","year":"2011"},{"key":"10.1002\/14651858.CD006332.pub4-BIB0057|cit57","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions. Version 6.1","author":"Higgins","year":"2020"},{"key":"10.1002\/14651858.CD006332.pub4-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary","volume":"17","author":"Jadad","year":"1996","journal-title":"Controlled Clinical Trials."},{"key":"10.1002\/14651858.CD006332.pub4-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"S235","DOI":"10.1016\/S0959-8049(16)30681-5","article-title":"Treatment with methylnaltrexone is associated with increased survival in patients with advanced refractory cancers treated for opioid induced constipation","volume":"51","author":"Janku","year":"2015","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD006332.pub4-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1007\/s11894-013-0344-2","article-title":"Opioid-induced bowel dysfunction","volume":"15","author":"Ketwarro","year":"2013","journal-title":"Current Gastroenterology Reports"},{"key":"10.1002\/14651858.CD006332.pub4-BIB0061|cit61","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-642-27233-2","volume-title":"Nutritional Management of Cancer Treatment Effects","author":"Kumar","year":"2012"},{"key":"10.1002\/14651858.CD006332.pub4-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"iv111","DOI":"10.1093\/annonc\/mdy148","article-title":"Diagnosis, assessment and management of constipation in advanced cancer: ESMO Clinical Practice Guidelines","volume":"29","author":"Larkin","year":"2018","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD006332.pub4-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1007\/s12325-010-0063-0","article-title":"The role of opioid receptor antagonists in the treatment of opioid-induced constipation: a review","volume":"27","author":"Leppert","year":"2010","journal-title":"Advances in Therapy"},{"key":"10.1002\/14651858.CD006332.pub4-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.2147\/DDDT.S32684","article-title":"Emerging therapies for patients with symptoms of opioid-induced bowel dysfunction","volume":"9","author":"Leppert","year":"2015","journal-title":"Drug Design, Development and Therapy"},{"key":"10.1002\/14651858.CD006332.pub4-BIB0065|cit65","first-page":"236045","article-title":"The burden of opioid-induced constipation: discordance between patient and health provider reports","volume":"22","author":"LoCasale","year":"2016","journal-title":"Journal of Management Care and Speciality Pharmacy"},{"key":"10.1002\/14651858.CD006332.pub4-BIB0066|cit66","first-page":"208","article-title":"Availability and utilization of opioids for pain management: global issues","volume":"14","author":"Manjiani","year":"2014","journal-title":"Ochsner Journal"},{"key":"10.1002\/14651858.CD006332.pub4-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"965","DOI":"10.2147\/TCRM.S3147","article-title":"Management of postoperative ileus: focus on alvimopan","volume":"4","author":"Marderstein","year":"2008","journal-title":"Therapeutics and Clinical Risk Management"},{"key":"10.1002\/14651858.CD006332.pub4-BIB0068|cit68","unstructured":"Pharmaceutical Manufacturing Research Services Highlights of prescribing information, 2015 www.merck.com\/product\/usa\/pi_circulars\/e\/entereg\/entereg_pi.pdf"},{"key":"10.1002\/14651858.CD006332.pub4-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.cgh.2018.01.021","article-title":"Efficacy of treatments for opioid-induced constipation: systematic review and meta-analysis","volume":"16","author":"Nee","year":"2018","journal-title":"Clinical Gastroenterology Hepatology"},{"key":"10.1002\/14651858.CD006332.pub4-BIB0070|cit70","unstructured":"National Institute for Clinical Execellence Naloxegol for treating opioid-induced constipation, 2015 nice.org.uk"},{"key":"10.1002\/14651858.CD006332.pub4-BIB0071|cit71","unstructured":"National Institute for Health and Care Excellence Opioids in palliative care: safe and effective prescribing of strong opioids for pain in palliative care of adults, 2012 www.nice.org.uk\/guidance\/cg140\/resources"},{"key":"10.1002\/14651858.CD006332.pub4-BIB0072|cit72","unstructured":"National Institute for Clinical Excellence Methylnaltrexone bromide for treating opioid-induced constipation (terminated appraisal), 2017 nice.org.uk"},{"key":"10.1002\/14651858.CD006332.pub4-BIB0073|cit73","unstructured":"National Institute for Clinical Excellence Naldemedine for treating opioid-induced constipation (TA651) nice.org.uk"},{"key":"10.1002\/14651858.CD006332.pub4-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1111\/j.1742-1241.2007.01415.x","article-title":"Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden","volume":"61","author":"Panchal","year":"2007","journal-title":"International Journal of Clinical Practice"},{"key":"10.1002\/14651858.CD006332.pub4-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"11S","DOI":"10.1016\/S0002-9610(01)00782-6","article-title":"Incidence, prevalence, and management of opioid bowel dysfunction","volume":"182","author":"Pappagallo","year":"2001","journal-title":"American Journal of Surgery"},{"key":"10.1002\/14651858.CD006332.pub4-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1002\/j.1875-9114.2012.01101.x","article-title":"Relationship between potential opioid-related adverse effects and hospital length of stay in patients receiving opioids after orthopedic surgery","volume":"32","author":"Pizzi","year":"2012","journal-title":"Pharmacotherapy"},{"key":"10.1002\/14651858.CD006332.pub4-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"272","DOI":"10.12968\/ijpn.2015.21.6.272","article-title":"Management of opioid-induced constipation for people in palliative care","volume":"21","author":"Pritchard","year":"2015","journal-title":"International Journal of Palliative Nursing"},{"key":"10.1002\/14651858.CD006332.pub4-BIB0078|cit78","unstructured":"Review Manager Web (RevMan Web) The Cochrane Collaboration 2020"},{"key":"10.1002\/14651858.CD006332.pub4-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-152-11-201006010-00232","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials","volume":"152","author":"Schulz","year":"2010","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD006332.pub4-BIB0080|cit80","volume-title":"Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach. GRADE Working Group","author":"Schu\u0308nemann","year":"2013"},{"key":"10.1002\/14651858.CD006332.pub4-BIB0081|cit81","unstructured":"NHS Scotland Scottish Palliative Care Guidelines: about the guidelines, 2014 www.palliativecareguidelines.scot.nhs.uk\/guidelines"},{"key":"10.1002\/14651858.CD006332.pub4-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1177\/1049909117705379","article-title":"Management of opioid-induced constipation in hospice patients","volume":"35","author":"Sera","year":"2018","journal-title":"American Journal of Hospice and Palliative Medicine"},{"key":"10.1002\/14651858.CD006332.pub4-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1191\/026921698674125048","article-title":"The relationship between opioid use and laxative use in terminally ill cancer patients","volume":"12","author":"Sykes","year":"1998","journal-title":"Palliative Medicine"},{"issue":"10","key":"10.1002\/14651858.CD006332.pub4-BIB0084|cit84","first-page":"1225","article-title":"Pharmacologic treatment of opioid-induced constipation","volume":"22","author":"Yuan","year":"2013","journal-title":"Drugs"},{"key":"10.1002\/14651858.CD006332.pub4-BIB0085|cit85","unstructured":"World Health Organization WHO's cancer pain ladder for adults, 2016 who.int\/cancer\/palliative\/painladder\/en\/"},{"issue":"1","key":"10.1002\/14651858.CD006332.pub4-BIB0086|cit86","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003448.pub3","article-title":"Laxatives or methylnaltrexone for the management of constipation in palliative care patients","author":"Candy","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD006332.pub4-BIB0087|cit87","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006332.pub3","article-title":"Mu-opioid antagonists for opioid induced bowel dysfunction in people with cancer and people receiving palliative care","author":"Candy","year":"2018","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD006332.pub4-BIB0088|cit88","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006332","article-title":"Mu-opioid antagonists for opioid-induced bowel dysfunction","author":"McNicol","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD006332.pub4-BIB0089|cit89","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006332.pub2","article-title":"Mu-opioid antagonists for opioid-induced bowel dysfunction","author":"McNicol","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T11:03:31Z","timestamp":1704366211000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD006332.pub4"}},"subtitle":[],"editor":[{"name":"Cochrane Pain, Palliative and Supportive Care Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,9,15]]},"references-count":89,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,9]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd006332.pub4","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,15]]}}}